Two senior doctors who co-founded Fullerton Healthcare Corporation (FHC) have been ordered to pay a combined fine of S$160,000 after pleading guilty to falsifying entertainment expense claims in Singapore. Daniel Chan Pai Sheng and Michael Tan Kim Song, both aged 52, admitted to account falsification charges that concealed inflated expenditures totalling more than S$211,000 during a period spanning several years. Yet despite the scale of the irregularities uncovered, neither man personally benefited from the scheme, which authorities determined was designed instead to channel funds to a third party whose case remains under review.
Chan faced the heavier penalty, receiving a S$135,000 fine after admitting to five counts of falsifying accounts on July 10. The documents reveal that claims submitted totalled more than S$336,000, whereas actual out-of-pocket costs amounted to approximately S$125,000, creating an inflated discrepancy exceeding S$211,000. Tan's culpability was narrower in scope; he received a S$25,000 fine for a single falsification charge connected to one of Chan's violations. The false entertainment claim in Tan's case was approximately S$82,000 against actual expenses of just over S$42,000, representing a fabricated amount of nearly S$40,000, which formed part of the broader scheme.
Court documents indicate that the elaborate arrangement was devised to provide financial assistance to Collin Chiew, a 58-year-old who previously served as chief executive of insurance broker Aon Singapore from January 2015 through July 2018. Chiew allegedly approached Chan in 2015 requesting money to support his children and housing costs. Rather than extending personal loans, Chan and Tan orchestrated a system involving falsified business entertainment receipts that would be processed through company accounts, effectively laundering assistance to Chiew through FHC's expense systems. Prosecutors have not disclosed whether Chiew ultimately received the full amount in question, and his case remains pending as authorities continue their investigation.
The falsification apparatus operated through a carefully constructed network involving multiple parties and locations. Beginning in 2015, when Chan commenced regular business trips to Hong Kong approximately twice monthly to advance FHC's operations there, he would request inflated or entirely fabricated karaoke venue receipts from co-founder David Sin and associate Tei Chu Pink, aged 46. During these Hong Kong visits, Chan would socialise at KTV establishments alongside Sin and Tei whilst ostensibly meeting potential investors. Upon collecting the doctored receipts, he would return to Singapore and distribute them to appropriate personnel within FHC or subsidiary Fullerton Health China, who would then process these false claims through company payment channels.
The mechanics of the deception revealed a deliberate effort to obscure the true nature of payments. Court documents state that on certain occasions, Chan would personally pay reduced amounts at the KTV venues using cash or credit cards, creating a veneer of legitimacy. On other instances, he made no payment whatsoever, yet still collected inflated receipts subsequently submitted as legitimate business expenses. This inconsistency—paying nothing while claiming significant entertainment costs—would have been difficult to reconcile during routine financial audits, suggesting the scheme relied either on inadequate oversight or deliberate negligence within FHC's accounting department. Tan maintained knowledge of numerous such claims and, alongside Sin, directly participated in at least one conspiracy to fabricate an entertainment expense claim in 2016.
Interestingly, the prosecution initially pursued graft-related charges against both men, reflecting suspicions that the arrangement might constitute corruption. However, Deputy Public Prosecutors Jonathan Tan and Ashley Chin applied for discharge not amounting to acquittal on all such charges, exercising prosecutorial discretion. District Judge Paul Quan approved this application on July 10, meaning that whilst the corruption charges were dismissed, they remain capable of resurrection if fresh evidence emerges that alters the investigative picture. This procedural manoeuvre underscores the complexity of proving corrupt intent when financial benefit to the accused cannot be established—a distinction that, whilst clearing them of graft allegations, does not diminish their accountability for falsification.
FHC itself operates as an investment holding entity, though its primary commercial activity flows through subsidiaries. Fullerton Healthcare Group (FHG), which Tan co-founded with Chan in 2010, functions as a healthcare services provider deploying a network of doctors and specialists whilst assisting clients with insurance claim processing. Fullerton Health China represents the group's international expansion, reflecting the broader commercial ambitions that prompted Chan's regular Hong Kong visits. These legitimate business operations provided convenient cover for the fictitious entertainment expenses, as regular travel to China and client entertainment could plausibly explain receipts from upmarket KTV venues, a category of business expense that many auditors might not scrutinise intensively.
The investigation's scope extended beyond the two convicted doctors. In August 2025, David Sin, the third FHC co-founder aged 47, pleaded guilty to six separate counts of falsifying accounts and received an identical S$160,000 fine. Sin's equal penalty despite facing more charges suggests either less significant individual sums per charge or judicial recognition that his role, whilst culpable, was somewhat less central than Chan's to orchestrating the scheme. The fact that three of FHC's founding partners have now been convicted of falsification offences raises serious questions about the corporate culture and internal controls that prevailed during the period in question, particularly whether financial oversight was deliberately weak or merely inadequately designed.
Neither Chan nor Tan currently holds positions within their former companies. Chan's removal as president of Fullerton Health China and Tan's departure from his director role at Fullerton Healthcare Group represent efforts at remediation following the convictions. However, the simultaneous conviction of the third co-founder creates significant reputational damage for the broader FHC group that may require board-level restructuring to restore stakeholder confidence. For Malaysian readers and the wider Southeast Asian business community, the case underscores the persistent risks of inadequate financial governance in rapidly expanding healthcare and investment companies, particularly those operating across multiple jurisdictions where coordination of compliance oversight becomes exponentially more challenging.
The S$211,000 in falsified claims, whilst substantial, remains relatively modest compared to the infrastructure and revenue of a multi-subsidiary holding company, suggesting either that investigators uncovered only the exposed portion of a larger scheme or that the principals deliberately restrained the operation to avoid triggering more aggressive auditing. The prosecution's decision to discharge graft charges rather than pursue them to verdict leaves unresolved the question of whether the arrangement constituted corrupt practice or merely embezzlement dressed in administrative falsification. This prosecutorial judgment likely reflects the difficulty of proving that Chiew was either a government official or that improper payments were intended to influence his actions at Aon Singapore, though the facts suggest conscious deception regardless of classification. The case ultimately demonstrates that sophisticated business environments require layered financial controls and independent audit functions capable of detecting the sophisticated manipulation of receipt and payment records across international operations.
